Shanghai Fosun To Take Control of Taiwan's Henlix for $98 Million

Shanghai Fosun Pharma will pay up to $98 million to buy the 69% of Henlix Biotech it doesn't already own. Henlix, founded by two US-biopharma veterans in 2010, is a Taiwan-San Francisco innovative biotech that is developing both biosimilars and novel drugs. It has at least four candidates that have either started clinical trials or filed for IND approvals. Fosun will purchase Henlix through its Fosun Henlius subsidiary, a Shanghai company that develops biosimilars. More details.... Stock Symbols: (SHA: 600196; HK: 2196) Share this with colleagues: // //